In its maiden M&A deal, SOPHiA Genetics has acquired Interactive Biosoftware (IBS), the French tech developer of Alamut, a suite of clinical decision applications for genomic analysis, for an undisclosed price. The Swiss analytics company said the acquisition is aimed at accelerating the adoption of its artificial intelligence (AI) platform for cancer diagnosis.
IBS' Alamut software suite includes Alamut Batch, an annotation software for next generation sequencing (NGS) analysis; Alamut Focus, a variant filtration application created to let users put forward genetic variations of interest; and Alamut Visual, a graphical software application designed to enable interactive exploration of